Exploring telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome (TELEACE): A real-world observational study.

Authors

null

Michael Morse

Duke University Medical Center, Durham, NC

Michael Morse , Eric Liu , Vijay N. Joish , Lynn Huynh , Mu Cheng , Todor Totev , Mei S. Duh , Pablo Lapuerta , David C. Metz

Organizations

Duke University Medical Center, Durham, NC, The Neuroendocrine Institute at Rocky Mountain Cancer Centers, Denver, CO, Lexicon Pharmaceuticals, Inc., The Woodlands, TX, Analysis Group, Inc., Boston, MA, University of Pennsylvania School of Medicine, Philadelphia, PA

Research Funding

Pharmaceutical/Biotech Company
Lexicon Pharmaceuticals, Inc

Background: Serotonin may have proliferative effects on neuroendocrine tumors (NETs). Inhibition of tryptophan hydroxylase (TPH), with resulting reduction of serotonin, may impact tumor size and growth (TG) in patients with NETs. We investigated the effects of TPH inhibitor telotristat ethyl (TE) on TG among patients receiving TE in clinical practice. Methods: A chart review study of 200 patients who had initiated TE was conducted. All patients had ≥2 radiological scans in the past 12 months prior to TE initiation and ≥1 scan post-TE initiation. Data were collected via a secure online portal. Descriptive statistics summarized physician and patient characteristics, and documented background NET treatment (i.e., somatostatin analog [SSA] and/or non-SSA). Longitudinal analyses of TG were assessed using a generalized linear regression model after controlling for documented background NET treatment and time since first scan. Results: Most physicians (71/114) were community-based oncologists. On average, patients were 61 ± 10 years old when initiating TE, 57% male, and 74% white; 61% had well-differentiated tumor with 61% of gastrointestinal origin. Patients received TE for an average of 12.0 ± 7.3 months and 82% (n = 163) were still receiving TE treatment at the time of data collection. The mean time from first scan to TE initiation was 5.6 ± 4.7 months and from TE initiation to last scan was 7.2 ± 6.3 months. Significant mean reductions in tumor size, after TE initiation, of 0.6 cm (p = 0.006) and TG of 8.5% (p = 0.045) were observed. Documented background NET treatment prior to initiating TE and time since first scan were not significant predictors of TG reduction. Results were consistent in a subset (n = 65) of patients who had no change in documented background NET treatment before and after initiating TE (mean reductions in tumor size 0.6 cm, p = 0.044 and TG 8.1%, p = 0.203). Conclusions: Treatment with TE may impact TG in patients with NETs. Prospective clinical studies are warranted to further examine the antiproliferative effects of TE.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 618)

Abstract #

618

Poster Bd #

F21

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Annual Meeting

Telotristat ethyl with PRRT in the treatment of well differentiated neuroendocrine tumors.

First Author: Tony Z. Zhuang

Abstract

2021 Gastrointestinal Cancers Symposium

Cost of treatment change among patients with neuroendocrine tumors (NET) treated originally with somatostatin analogs.

First Author: Bernard Tawfik